Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Explore linked clinical trials.18 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Not yet recruiting | Phase 2 / Phase 3 | 2026-10-05 | NCT07859423 | |
| A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, pyruvate kinase deficiency of red cells, sickle cell disease, thalassemia | Enrolling by invitation | Phase 4 | 2026-09-29 | NCT05777993 | |
| A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease | Recruiting | Phase 3 | 2026-09-28 | NCT07656415 | |
| A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia | Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia | Recruiting | Phase 3 | 2026-09-28 | NCT07517133 | |
| A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) | Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia | Recruiting | Phase 3 | 2026-09-28 | NCT07506863 | |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, hereditary disease, inborn disorder of amino acid metabolism, inborn errors of metabolism, metabolic disease, nervous system disorder, phenylketonuria | Recruiting | Phase 1 | 2026-09-28 | NCT07241234 | |
| A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease | Active, not recruiting | Phase 2 | 2026-09-28 | NCT06924970 | |
| A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) | Hemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Active, not recruiting | Phase 2 | 2026-09-28 | NCT05490446 | |
| A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period | Hemic and Lymphatic Diseases, Nutritional and Metabolic Diseases, anemia, hematologic disorder, metabolic disease, pyruvate kinase deficiency of red cells | Active, not recruiting | Phase 3 | 2026-09-28 | NCT05144256 | |
| A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) | Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia | Active, not recruiting | Phase 3 | 2026-09-28 | NCT04770779 | |
| A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) | Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia | Active, not recruiting | Phase 3 | 2026-09-28 | NCT04770753 | |
| Pyruvate Kinase Deficiency Global Longitudinal Registry | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, congenital nonspherocytic hemolytic anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, pyruvate kinase deficiency of red cells | Active, not recruiting | Not stated | 2026-09-28 | NCT03481738 | |
| A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period | Hemic and Lymphatic Diseases, Nutritional and Metabolic Diseases, anemia, hematologic disorder, metabolic disease, pyruvate kinase deficiency of red cells | Active, not recruiting | Phase 3 | 2026-08-27 | NCT05175105 | |
| A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants | Healthy Participants | Active, not recruiting | Phase 1 | 2026-07-30 | NCT07075640 | |
| A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease | Active, not recruiting | Phase 2 / Phase 3 | 2026-06-23 | NCT05031780 | |
| AG-120 in People With IDH1 Mutant Chondrosarcoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, chondrosarcoma, connective tissue neoplasm, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, sarcoma | Active, not recruiting | Phase 2 | 2026-04-23 | NCT04278781 | |
| A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, thalassemia | Active, not recruiting | Phase 2 | 2026-03-30 | NCT03692052 | |
| To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of the Drug in Patients With RBC Membranopathies or CDAII. | Hemic and Lymphatic Diseases, anemia, hematologic disorder | Recruiting | Phase 2 | 2025-07-08 | NCT07055243 |